EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?

Hong-Li Guo, Jian Huang, Jie Wang, Lin Fan, Yue Li, Dan-Dan Wu, Qian-Qi Liu, Feng Chen

Frontiers in Pharmacology · 29.10.2024 · 15

DOI: 10.3389/fphar.2024.1484512 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.10.2024. Verfasst von Hong-Li Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-stimulant atomoxetine is recognized in various current clinical guidelines as an important alternative to stimulants for the pharmacological treatment of attention deficit/hyperactivity disorder (ADHD) in children. While its efficacy and tolerability for core symptoms are established, there is considerable inter-individual variability in response and exposure, highlighting the need for personalized dosing. In this review, we evaluated existing studies and summarized comprehensive evidence supporting the clinical implementation of therapeutic drug monitoring (TDM) and personalized dosing of atomoxetine, organized around a series of logically structured questions. Although there are notable gaps in achieving personalized dosing across multiple critical elements, the available evidence is helpful to endorse personalized dose adjustments based on TDM and CYP2D6 genotyping “whenever possible.” We advocate for ongoing improvement and enhancement in clinical practice. Future advancements will rely on a deeper understanding of ADHD, facilitating more precise diagnoses and personalized treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

CYP2D6atomoxetineattention deficit/hyperactivity disorder (ADHD)biomarkerschildreninter-individual variabilityprecision pharmacotherapytherapeutic drug monitoring (TDM)

Autor:innen und Institutionen

  • Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Children Healthcare, Children's Hospital of Nanjing Medical University, Nanjing, China.

Zitieren

APA

Guo, H. L., Huang, J., Wang, J., Fan, L., Li, Y., Wu, D. D., Liu, Q. Q., & Chen, F. (2024). Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1484512

Vancouver

Guo HL, Huang J, Wang J, Fan L, Li Y, Wu DD, et al. Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1484512

BibTeX
@article{Guo2024,
  author = {Guo, Hong-Li and Huang, Jian and Wang, Jie and Fan, Lin and Li, Yue and Wu, Dan-Dan and Liu, Qian-Qi and Chen, Feng},
  title = {Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1484512}
}
Kostenlos starten →